stockrow
Saturday 7 November 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
1.97
0.12
−5.74%
Follow MCRB
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 2 | 1 | 5 | 3 | 2 | 2 | — | — |
P/E ratio |
22.21 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
89.49 | — | 1.42 | 81.88 | 5.27 | 58.85 | 5.66 | 6.52 | 13.29 | 18.33 |
Altman Z-Score |
(10.99) | — | (4.74) | (3.70) | 0.19 | 4.76 | (5.25) | (5.88) | (0.68) | 0.49 |
Altman Z″-Score (non-manufacturers) |
(25.59) | — | (11.26) | (9.46) | (2.15) | (1.60) | (12.56) | (13.67) | (3.01) | 0.66 |
P/FCF ratio |
122.63 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.78 |
P/Operating CF |
(8.96) | — | (3.77) | (11.03) | (14.73) | (109.05) | (13.91) | 14.54 | (20.71) | (19.17) |
Beneish M-Score |
— | — | — | — | — | 2.11 | — | — | — | — |
P/B ratio |
2.98 | — | 0.00 | 54.12 | 5.81 | 11.19 | 0.00 | 0.00 | 7.03 | 3.01 |
Price to Tangible BV |
2.98 | — | 0.00 | 54.12 | 5.81 | 11.19 | 0.00 | 0.00 | 7.03 | 3.01 |
EV/Sales |
128.00 | — | 1.21 | 63.53 | 3.44 | 51.96 | 3.63 | 3.72 | 8.90 | 9.94 |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
168.80 | — | (1.30) | (1.98) | 74.44 | (18.44) | (1.64) | (1.67) | (3.78) | 4.93 |
EV/FCF |
175.40 | — | (1.22) | (1.90) | (172.98) | (18.32) | (1.62) | (1.62) | (3.56) | 9.65 |
Quick Ratio |
2.40 | 0.80 | 1.39 | 2.12 | 3.53 | 5.67 | 2.10 | 2.04 | 4.74 | 6.34 |
Current Ratio |
2.56 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
Net Debt/EBITDA |
0.51 | 0.27 | 0.14 | 0.76 | 4.79 | 2.84 | 1.09 | 0.85 | 1.67 | 2.05 |
Debt/Assets |
0.00% | 0.00% | 28.32% | 14.50% | 6.94% | 7.18% | 18.61% | 5.62% | 4.74% | 3.94% |
Debt/Equity |
0.00 | 0.00 | (2.26) | 4.69 | 0.19 | 0.14 | (0.51) | (0.14) | 0.15 | 0.08 |
Asset Turnover |
0.01 | 0.00 | 0.36 | 0.02 | 0.42 | 0.14 | 0.27 | 0.18 | 0.14 | 0.09 |
Operating CF/Net income |
0.20 | (1,092.71) | 1.03 | 0.91 | (0.10) | 1.05 | 1.09 | 0.64 | 0.85 | (0.48) |
Capex/Depreciation |
(0.01) | (0.06) | (1.12) | (1.22) | (1.07) | (0.08) | (0.13) | (0.25) | (0.66) | (5.63) |
Interest Coverage |
— | — | (79.05) | (29.89) | (22.16) | (30.14) | (143.18) | (85.57) | (57.48) | (41.65) |
| 19.64% | (0.88%) | 667.53% | (351.62%) | (42.83%) | (140.99%) | 145.85% | (1,563.81%) | (92.46%) | (54.18%) | |
| 4.10% | 0.05% | (32.15%) | (71.10%) | (18.80%) | (37.50%) | (55.58%) | (63.83%) | (38.68%) | (37.41%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
15.11% | 1.51% | (120.52%) | (189.29%) | (27.40%) | (37.72%) | (95.37%) | (128.63%) | (57.15%) | (44.88%) |
Average Days of Receivables |
239.17 | 0.00 | 25.06 | 0.00 | 0.00 | 103.15 | 18.88 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
6,218.00% | 0.00% | 93.09% | 1,538.31% | 97.91% | 272.68% | 232.26% | 339.46% | 278.68% | 376.68% |
Selling, General and Administrative Expense of Revenue |
4,962.74% | 0.00% | 61.35% | 985.73% | 47.79% | 92.65% | 71.72% | 115.31% | 106.04% | 149.85% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1,373.89% | 0.00% | 26.99% | 357.49% | 13.95% | 26.57% | 24.18% | 58.87% | 54.09% | 77.45% |
Graham Net Nets |
(0.34) | — | (1.27) | (0.25) | 0.11 | 0.05 | (0.41) | (0.41) | 0.06 | 0.15 |
Graham Number |
8.67 | — | 53.28 | 0.00 | 0.00 | 0.00 | 100.29 | 160.59 | 0.00 | 0.00 |
Earnings Yield |
4.50% | — | (64.29%) | (43.33%) | (8.76%) | (4.49%) | (37.97%) | (53.76%) | (20.85%) | (22.88%) |
Free Cash Flow Yield |
0.82% | — | (69.94%) | (40.89%) | (0.38%) | (4.82%) | (39.66%) | (35.18%) | (18.79%) | 5.62% |
Revenue per Share |
0.09 | 0.00 | 19.74 | 1.32 | 31.61 | 8.33 | 12.18 | 13.88 | 15.87 | 10.92 |
Operating CF per Share |
0.13 | (19.13) | (18.34) | (42.34) | 1.46 | (23.46) | (27.01) | (30.85) | (37.34) | 22.04 |
Capex per Share |
0.00 | (0.05) | (1.25) | (1.82) | (2.09) | (0.15) | (0.35) | (0.95) | (2.31) | (10.79) |
Free Cash Flow per Share |
0.12 | (19.17) | (19.58) | (44.16) | (0.63) | (23.61) | (27.37) | (31.80) | (39.65) | 11.26 |
Cash per Share |
5.17 | 3.96 | 19.99 | 33.56 | 63.40 | 63.57 | 33.47 | 42.13 | 74.16 | 96.99 |
Shareholders Equity per Share |
4.99 | 1.77 | (7.01) | 2.00 | 28.68 | 43.80 | (17.06) | (23.58) | 30.01 | 66.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.99 | 1.77 | (7.01) | 2.00 | 28.68 | 43.80 | (17.06) | (23.58) | 30.01 | 66.57 |
Free Cash Flow |
1.08 | (148.99) | (125.33) | (238.64) | (2.88) | (94.20) | (77.52) | (64.79) | (80.20) | 22.43 |
Working Capital |
30.05 | (2.55) | 76.75 | 109.17 | 221.37 | 222.36 | 54.20 | 50.62 | 123.45 | 167.91 |
Capital Expenditures |
(0.04) | (0.38) | (7.97) | (9.82) | (9.57) | (0.59) | (1.00) | (1.94) | (4.68) | (21.49) |
Net Current Asset Value |
(44.60) | (87.35) | (228.05) | (143.24) | 80.28 | 100.59 | (80.57) | (75.85) | 26.26 | 58.35 |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.00 | 0.06 | 1.38 | 0.07 | 0.02 | 0.03 | 0.07 | 0.15 | 0.99 |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.54 | 0.60 | 0.41 | 0.35 | 0.50 | 0.55 | 0.40 | 0.29 | 0.21 | 0.11 |
Cash ROIC |
1.19% | (334.23%) | (67.87%) | (98.32%) | (0.64%) | (20.79%) | (108.97%) | (145.43%) | (36.51%) | 6.66% |
Accounts Receivable Turnover |
0.61 | 0.00 | 13.99 | 0.00 | 0.00 | 5.95 | 6.18 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Average Receivables |
1.29 | 5.37 | 9.03 | — | — | 5.59 | 5.59 | — | — | — |
Average Payables |
2.88 | 3.86 | 10.54 | 15.59 | 8.88 | 4.44 | 5.64 | 6.72 | 7.31 | 6.49 |
Average Assets |
139.00 | 249.21 | 353.69 | 351.82 | 348.90 | 237.69 | 126.46 | 155.00 | 231.08 | 244.77 |
Average Common Equity |
29.00 | (15.54) | (17.04) | 71.15 | 153.13 | 63.21 | (48.18) | 6.33 | 96.67 | 169.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026